TG Therapeutics, Inc. (TGTX)


-1.71 (-6.29%)
Symbol TGTX
Price $25.49
Beta 2.081
Volume Avg. 4.26M
Market Cap 3.808B
Shares () -
52 Week Range 3.48-35.67
1y Target Est -
DCF Unlevered TGTX DCF ->
DCF Levered TGTX LDCF ->
ROE -173.03% Strong Sell
ROA -102.46% Strong Sell
Operating Margin -
Debt / Equity 230.40% Strong Buy
P/E -20.56 Strong Sell
P/B 58.91 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest TGTX news

Mr. Michael S. Weiss Esq.
NASDAQ Capital Market

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.